# DESCRIPTION

- claim priority and disclose government support

## FIELD

- define field of invention

## BACKGROUND

- motivate oncolytic virus therapy
- summarize limitations of SVV development

## SUMMARY

- outline method for selecting cancer patient
- outline method for treating cancer
- describe kit for selecting cancer patient

## DETAILED DESCRIPTION

- introduce patent application structure
- define terms and conventions used throughout application

### ANTXR1 is a Targetable Cellular Receptor for SVV on Tumors

- describe ANTXR1 function and uniqueness
- discuss ANTXR1 expression on tumor cells
- highlight potential therapeutic applications

### Definitions

- define cancer, tumor, and tumor cells
- define virus, derivative, mutant, variant, and modified virus

### Methods for Patient Screening

- introduce method for selecting cancer patients for SVV treatment
- determine ANTXR1 expression level in cancerous tissue
- designate patient as candidate for SVV treatment
- optionally determine expression profile of other biomarkers
- detect expression of ANTXR1 and other biomarkers
- describe immunohistochemistry detection method
- describe ELISA detection method
- describe antibody microarray detection method
- describe oligonucleotide microarray detection method
- discuss microarray panel processing modes
- discuss image analysis and report generation

### Treatment Methods

- describe method for treating cancer using SVV

### Administration

- describe SVV administration to host or subject
- discuss dosage and therapeutic index
- describe delivery methods and combination therapy

### Formulation

- formulate pharmaceutical composition
- describe composition characteristics

### Combination Therapy

- describe combination with immunotherapy
- outline adjunct therapies
- list additional active agents

### Kit

- describe kit for selecting cancer patients

## EXAMPLES

### Example 1: Materials and Methods

- list reagents and bacterial strains
- describe cell lines and viruses
- outline human GeCKO v2 library
- detail individual sgRNA plasmids
- construct inducible ANTXR1 expression plasmid
- clone ANTXR1-HA expression plasmid truncations
- produce lentivirus
- transduce lentivirus
- screen GeCKO library
- identify sgRNAs
- perform CRISPR secondary screens
- assess cell viability
- analyze cell viability data
- identify ANTXR1 indels in ANTXR1 KO lines
- generate ANTXR1-KO lines
- create H446 ANTXR1 KO mCherry cell line
- perform in vivo SW-001 efficacy experiment
- conduct ANTXR1 expression experiments
- perform SVV-GFP infections
- conduct SVV-Cy5 binding experiment
- perform co-immunoprecipitations
- perform Western blotting
- analyze flow cytometry data
- perform gene expression analysis
- determine ANTXR1 expression cutoff
- identify differentially expressed genes
- perform gene set enrichment analysis
- perform cryo-electron microscopy
- reconstruct SVV-ANTXR1 complex structure

### Example 2: Genome-Wide Loss-of-Function Screens Identify ANTXR1 as Essential for SVV Infection

- perform GeCKO screen in HAP1 cells
- identify ANTXR1 as essential gene for SVV infection
- confirm results in H446 SCLC cell line

### Example 3: ANTXR1 is Necessary for Permissively in Neuroendocrine Cancer Cell Lines

- generate ANTXR1 KO clones in H446 cells
- confirm loss of SVV permissivity in ANTXR1 KO clones
- test ANTXR1 KO clones in mixed cell population

### Example 4: Defects in Innate Immune Signaling are Required for SVV Replication

- analyze ANTXR1 expression in CCLE dataset
- identify association between ANTXR1 expression and permissivity
- identify differentially expressed gene sets between permissive and non-permissive cell lines
- analyze gene set enrichment in permissive cell lines
- test IFN pathway activity in ANTXR1-expressing cell lines

### Example 5: Re-Expression of ANTXR1 Rescues SVV Permissivity

- re-express ANTXR1 in ANTXR1 KO cells and test SVV permissivity

### Example 6: Ectopic Expression of ANTXR1 is Sufficient to Induce SVV Permissivity

- express ANTXR1 in non-permissive SCLC cell lines and test SVV permissivity

### Example 7: ANTXR1 Interacts Directly with SVV

- perform co-immunoprecipitation studies with ANTXR1-Fc chimera
- test interaction strength under high ionic strength and with ANTXR2-Fc chimera

### Example 8: Soluble ANTXR1-Fc Chimera Blocks SVV Infection In Vitro

- test ability of ANTXR1-Fc chimera to block SVV infection in vitro

### Example 9: Loss of ANTXR1 Protein Expression Abrogates SVV Binding to Permissive Cells

- determine SVV binding to ANTXR1 KO cells
- assess TEX2 role in SVV binding
- analyze fluorescence profiles
- conclude ANTXR1 as major binding determinant

